Fewer Observations, Shift In Emphasis Seen In FDA's Pandemic-Reduced Inspections
US agency mostly saw less of the same when it scaled back inspectional activity during COVID-19, but observed more training and equipment issues.
US agency mostly saw less of the same when it scaled back inspectional activity during COVID-19, but observed more training and equipment issues.